Northeast Ohio Medical University

Northeast Ohio Medical University, doing business as Neomed, is a U.S. government entity and Ohio state-controlled institution of higher learning headquartered in Rootstown, Ohio, that operates as a federal grant recipient (87% of recent awards) and contract prime delivering medical education services and biomedical research to federal agencies. Neomed competes full-and-open with no set-aside designations; the vendor is a public university and therefore ineligible for SBA certifications.

Neomed's federal footprint is sharply concentrated in two mission areas. First, it provides tuition and educational services for military medical students through the Department of the Navy Bureau of Medicine and Surgery, which accounts for 50 awards and $3.7 million in combined potential value—roughly 84% of the vendor's contract dollars. Recent delivery orders include a $473,915 contract (awarded July 1, 2025, completing July 31, 2026) and a $51,749 contract (awarded February 27, 2025, completing July 31, 2025) for tuition and fees for military students pursuing medicine, pharmacy, and related health professions. Neomed holds a single-award Basic Ordering Agreement with the Bureau of Medicine and Surgery running through March 31, 2035, with no stated ceiling, under which these delivery orders are placed. Second, Neomed is a prolific federal research grant recipient, primarily from the National Institutes of Health and the Health Resources and Services Administration, conducting biomedical research in neurodegenerative disease, cardiovascular health, metabolic disorders, and hearing science. The NIH National Institute on Deafness and Other Communication Disorders, the NIH National Heart Lung and Blood Institute, and the NIH National Institute on Aging collectively fund work in auditory circuit development, coronary microvascular dysfunction, Alzheimer's disease mechanisms, and aging-related pathology. Representative grants include a $336,355 NIGMS Project Grant (awarded April 1, 2026, completing January 31, 2031) investigating sex chromosome and hormone impacts on drug metabolism; a $611,680 NIA Project Grant (awarded February 1, 2026, completing January 31, 2031) on vascular smooth muscle O-GlcNAcylation in metabolic syndrome; and a $1.48 million Defense Health Agency Military Medical Research and Development award (awarded August 1, 2023, completing July 31, 2027) on Parkinson's disease cognitive dysfunction modeling.

Activity has grown from 11 awards in 2022 to 22 in 2024, settling at 18 in 2025 and four through early 2026—a trajectory suggesting peak activity in 2024. Eleven awards (combined potential value $474,000) face ultimate completion within the next twenty-four months and will require recompete. The vendor operates across 41 federal customer agencies; the top five—Department of the Navy Bureau of Medicine and Surgery, NIH broadly, NIDCD, the Health Resources and Services Administration, and the NIH National Heart Lung and Blood Institute—account for 51% of recent award count. In its subcontract role, Neomed conducts collaborative research as a sub-recipient on NIH-funded projects through prime grants held by Florida State University, Case Western Reserve University, Kent State University, Carnegie Mellon University, the University of Michigan, and the Cleveland Clinic Foundation, contributing proteomics analysis, physiological studies, histological processing, and mouse model work. Combined obligated dollars across the portfolio exceed $225 million, substantially exceeding the $4.4 million in combined potential value—a signal that the obligated figure reflects multi-year, established award funding drawn down over time rather than newly awarded capacity.